Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PRO1102

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ProfoundBio

Drug class:

HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor

Related drugs:

‹

topotecan episcleral (0)

ado-trastuzumab emtansine (97)

fam-trastuzumab deruxtecan-nxki (90)

disitamab vedotin (27)

trastuzumab duocarmazine (6)

PF-06804103 (4)

MF-TTZ-MMAE (1)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

HER-2 expression	Gastrointestinal Cancer	HER-2 expression	Gastrointestinal Cancer	PRO1102 Sensitive: D – Preclinical PRO1102 Sensitive : D	PRO1102 Sensitive: D – Preclinical PRO1102 Sensitive : D
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	PRO1102 Sensitive: D – Preclinical PRO1102 Sensitive : D	PRO1102 Sensitive: D – Preclinical PRO1102 Sensitive : D